Cargando…

Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study

BACKROUND: Median overall survival (OS) after diagnosis of glioblastoma (GBM) remains 15 months amongst patients receiving aggressive surgical resection, chemotherapy and irradiation. Treatment of patients with a poor preoperative Karnofsky Performance Status Scale (KPSS) is still controversial. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Barz, Melanie, Gerhardt, Julia, Bette, Stefanie, Aftahy, A. Kaywan, Huber, Thomas, Combs, Stephanie E., Ryang, Yu-Mi, Wiestler, Benedikt, Skardelly, Marco, Gepfner-Tuma, Irina, Behling, Felix, Schmidt-Graf, Friederike, Meyer, Bernhard, Gempt, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591917/
https://www.ncbi.nlm.nih.gov/pubmed/34781889
http://dx.doi.org/10.1186/s12883-021-02424-0
_version_ 1784599356529180672
author Barz, Melanie
Gerhardt, Julia
Bette, Stefanie
Aftahy, A. Kaywan
Huber, Thomas
Combs, Stephanie E.
Ryang, Yu-Mi
Wiestler, Benedikt
Skardelly, Marco
Gepfner-Tuma, Irina
Behling, Felix
Schmidt-Graf, Friederike
Meyer, Bernhard
Gempt, Jens
author_facet Barz, Melanie
Gerhardt, Julia
Bette, Stefanie
Aftahy, A. Kaywan
Huber, Thomas
Combs, Stephanie E.
Ryang, Yu-Mi
Wiestler, Benedikt
Skardelly, Marco
Gepfner-Tuma, Irina
Behling, Felix
Schmidt-Graf, Friederike
Meyer, Bernhard
Gempt, Jens
author_sort Barz, Melanie
collection PubMed
description BACKROUND: Median overall survival (OS) after diagnosis of glioblastoma (GBM) remains 15 months amongst patients receiving aggressive surgical resection, chemotherapy and irradiation. Treatment of patients with a poor preoperative Karnofsky Performance Status Scale (KPSS) is still controversial. Therefore, we retrospectively assessed the outcome after surgical treatment in patients with a KPSS of ≤60%. METHODS: We retrospectively included patients with a de-novo glioblastoma WHO °IV and preoperative KPSS ≤60%, who underwent surgery at two neurosurgical centres between September 2006 and March 2016. We recorded pre- and postoperative tumour volume, pre- and postoperative KPSS, OS, age and MGMT promoter status. RESULTS: One hundred twenty-three patients (58 females/65 males, mean age 67.4 ± 13.4 years) met the inclusion criteria. Seventy-five of the 123 patients (61%) underwent surgical resection. 48/123 patients (39%) received a biopsy. The median preoperative and postoperative tumour volume of all patients was 33.0 ± 31.3 cm(3) (IR 15.0–56.5cm(3)) and 3.1 ± 23.8 cm(3) (IR 0.2–15.0 cm(3)), respectively. The median KPSS was 60% (range 20–60%) preoperatively and 50% (range 0–80%) postoperatively. Patients who received a biopsy showed a median OS for patients who received a biopsy only was 3.0 months (95% CI 2.0–4.0 months), compared to patients who had a resection and had a median OS of 8 months (95% CI 3.1–12.9 months). Age (p < 0.001, HR: 1.045 [95% CI 1.022–1.068]), postoperative tumour volume (p = 0.02, HR: 1.016 [95% CI 1.002–1.029]) and MGMT promotor status (p = 0.016, HR: 0.473 [95% CI 0.257–0.871]) were statistically significant in multivariate analysis. In subgroup analyses only age was shown as a significant prognostic factor in multivariate analyses for patients receiving surgery (p < 0.001, HR: 1.046 [95% CI 1.022–1.072]). In the biopsy group no significant prognostic factors were shown in multivariate analysis. CONCLUSION: GBM patients with a preoperative KPSS of ≤60% might profit from surgical reduction of tumour burden.
format Online
Article
Text
id pubmed-8591917
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85919172021-11-15 Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study Barz, Melanie Gerhardt, Julia Bette, Stefanie Aftahy, A. Kaywan Huber, Thomas Combs, Stephanie E. Ryang, Yu-Mi Wiestler, Benedikt Skardelly, Marco Gepfner-Tuma, Irina Behling, Felix Schmidt-Graf, Friederike Meyer, Bernhard Gempt, Jens BMC Neurol Research Article BACKROUND: Median overall survival (OS) after diagnosis of glioblastoma (GBM) remains 15 months amongst patients receiving aggressive surgical resection, chemotherapy and irradiation. Treatment of patients with a poor preoperative Karnofsky Performance Status Scale (KPSS) is still controversial. Therefore, we retrospectively assessed the outcome after surgical treatment in patients with a KPSS of ≤60%. METHODS: We retrospectively included patients with a de-novo glioblastoma WHO °IV and preoperative KPSS ≤60%, who underwent surgery at two neurosurgical centres between September 2006 and March 2016. We recorded pre- and postoperative tumour volume, pre- and postoperative KPSS, OS, age and MGMT promoter status. RESULTS: One hundred twenty-three patients (58 females/65 males, mean age 67.4 ± 13.4 years) met the inclusion criteria. Seventy-five of the 123 patients (61%) underwent surgical resection. 48/123 patients (39%) received a biopsy. The median preoperative and postoperative tumour volume of all patients was 33.0 ± 31.3 cm(3) (IR 15.0–56.5cm(3)) and 3.1 ± 23.8 cm(3) (IR 0.2–15.0 cm(3)), respectively. The median KPSS was 60% (range 20–60%) preoperatively and 50% (range 0–80%) postoperatively. Patients who received a biopsy showed a median OS for patients who received a biopsy only was 3.0 months (95% CI 2.0–4.0 months), compared to patients who had a resection and had a median OS of 8 months (95% CI 3.1–12.9 months). Age (p < 0.001, HR: 1.045 [95% CI 1.022–1.068]), postoperative tumour volume (p = 0.02, HR: 1.016 [95% CI 1.002–1.029]) and MGMT promotor status (p = 0.016, HR: 0.473 [95% CI 0.257–0.871]) were statistically significant in multivariate analysis. In subgroup analyses only age was shown as a significant prognostic factor in multivariate analyses for patients receiving surgery (p < 0.001, HR: 1.046 [95% CI 1.022–1.072]). In the biopsy group no significant prognostic factors were shown in multivariate analysis. CONCLUSION: GBM patients with a preoperative KPSS of ≤60% might profit from surgical reduction of tumour burden. BioMed Central 2021-11-15 /pmc/articles/PMC8591917/ /pubmed/34781889 http://dx.doi.org/10.1186/s12883-021-02424-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Barz, Melanie
Gerhardt, Julia
Bette, Stefanie
Aftahy, A. Kaywan
Huber, Thomas
Combs, Stephanie E.
Ryang, Yu-Mi
Wiestler, Benedikt
Skardelly, Marco
Gepfner-Tuma, Irina
Behling, Felix
Schmidt-Graf, Friederike
Meyer, Bernhard
Gempt, Jens
Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study
title Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study
title_full Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study
title_fullStr Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study
title_full_unstemmed Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study
title_short Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study
title_sort prognostic value of tumour volume in patients with a poor karnofsky performance status scale – a bicentric retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591917/
https://www.ncbi.nlm.nih.gov/pubmed/34781889
http://dx.doi.org/10.1186/s12883-021-02424-0
work_keys_str_mv AT barzmelanie prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT gerhardtjulia prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT bettestefanie prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT aftahyakaywan prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT huberthomas prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT combsstephaniee prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT ryangyumi prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT wiestlerbenedikt prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT skardellymarco prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT gepfnertumairina prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT behlingfelix prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT schmidtgraffriederike prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT meyerbernhard prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy
AT gemptjens prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy